Top Antibodies Technology Solution In APAC

We’re thrilled to present the Top Antibodies Technology Solution In APAC, a prestigious honor recognizing the industry’s game-changers. These exceptional businesses were nominated by our subscribers based on impeccable reputation and the trust these companies have garnered from our valued subscribers. After an intense selection process—led by C-level executives, industry pioneers and our expert editorial team—only the best have made the cut. These companies have been selected as recipients of the award, celebrating their leadership and innovation.

Nominate a Company ×

Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.

* 

Enter the code below: *

Can't read the image? click here to refresh

Submit

Thank You!

We are glad to receive your nomination. Our editorial team and evaluation panel will review your submission. Thank you for taking the time to highlight an organization driving impactful change in Lifescience Review.

Data not inserted

Top Antibodies Technology Solution In APAC

Click here to Nominate a Company
★Featured Companies

GL BIOCHEM
Read full profile →
GL BIOCHEM is a Shanghai-based peptide manufacturer that industrializes complex peptide science at scale, delivering reagents, custom synthesis and cGMP-grade materials. With 28 years of experience, it supplies global life sciences with ... read full profile

ADBIOTECH
Read full profile →
ADBIOTECH is a South Korean biotech firm specializing in innovative antibody solutions for animal health. Leveraging proprietary IgY and nanobody platforms, the company develops targeted treatments that address antibiotic resistance and ... read full profile

Adagene
Adagene is a global clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer. It is driven by a powerful platform combining computational biology and artificial intelligence. It creates antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. Its discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be best in class.

Akeso, Inc.
Akeso, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative biologic medicines. It develops best-in-class therapies including bispecific and multispecific antibodies, ADCs, mRNA and cell therapies. With a diversified pipeline covering cancer, autoimmune, inflammation, metabolic, and neurological issues, Akeso aims to address unmet medical needs globally.

Novamab
Novamab is a clinical stage biopharma company dedicated to creating life changing therapies for patients through innovative VHH technology. It is focused on developing innovative single-domain antibody drugs. Novamab develops therapies and innovates product lines targeting respiratory diseases (e.g., asthma, COPD), autoimmune disorders, and inflammatory bowel disease (IBD). It maintains a full research and development, CMC and GMP-scale production system, and holds dozens of patents positioning itself as a pioneer in nanobody drug development.

XDC
XDC is a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody drug conjugates (ADCs). It provides services from discovery, chemical payload and linker synthesis, and antibody production to full GMP manufacturing of drug substances and final drug products through laboratories and manufacturing facilities, allowing for significant reduction in development timelines and costs. Its global network delivers expert-driven, high-quality, and right first time project execution for its customers.

Antibodies News